PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. The THSNA 2020 program will include on demand access to recorded talks covering four educational tracks as well as live panel discussion sessions, a nursing workshop, digital posters, corporate symposia, and a virtual exhibit hall with commercial booths.

Note that all timea are listed in Eastern Daylight Time (EDT) and any aspect of this program is subject to change.

  Tue - Oct 27      Wed - Oct 28      Thu - Oct 29      Fri - Oct 30   

TUESDAY, OCTOBER 27

10:00 - 11:35 AM
PLENARY SESSION
PLENARY 1: EMBRACING CHANGE: FROM NEW DISCOVERIES TO NEW TREATMENTS TO IMPROVED PRACTICES
Chair/Organizer: Peter Kouides, Cathy Hayward

The opening Plenary of THSNA will showcase discoveries and advances in the fields of thrombosis and hemostasis, with broad perspectives and examples of exciting changes. The expert presenters will cover important basic discoveries and advances that have been enabled by translating discoveries to improve the understanding, diagnosis and care of people with bleeding and thrombotic problems.



OPENING REMARKS
Peter Kouides. THSNA President


ANTICOAGULANT STEWARDSHIP IN THE ERA OF NOVEL THERAPEUTICS
Allison Burnett. University of New Mexico United States


BUILDING FROM BASIC BIOLOGY TO IMPROVE DIAGNOSIS AND CARE.
David Ginsburg. Howard Hughes Medical Institute, University of Michigan


ADAPTING TO NEW THERAPEUTIC OPTIONS: IMPLICATIONS FOR CLINICAL SERVICES AND COAGULATION LABORATORIES
Rajiv Pruthi. Mayo Clinic

12:15 - 1:15 PM
SATELLITE SYMPOSIUM
CORPORATE LUNCH SYMPOSIUM: ASK THE EXPERTS: MANAGING YOUR PATIENTS WITH HEMOPHILIA A IN A VIRTUAL WORLD (LIVE ONLY - NOT RECORDED)

Sponsored By: Genentech, Inc.

Join the experts in hemophilia A as they discuss their experiences of managing patients in a virtual setting. They'll share clinical efficacy and safety data, along with any strategies they used to introduce patients to or manage patients on a subcutaneous prophylaxis. A live Q&A session will be held after to answer any questions. Don't miss out on this opportunity to learn more about a different kind of prophylaxis that may be right for your hemophilia A patients.

The discussion will be led by Shannon Meeks, MD, and feature Michael Callaghan, MD, and Jennifer Maahs, NP.



CORPORATE LUNCH SYMPOSIUM: CO-MORBIDITIES AND PHARMACOKINETICS IN PATIENTS WITH HEMOPHILIA; A CASE-BASED DISCUSSION

Sponsored By: Bayer

An overview of co-morbidities affecting aging in hemophilia, treatment considerations, and the importance of adapting and individualizing therapy with pharmacokinetic management. Discussion of interactive, practical case studies. This program is hosted and presented by Dr. Stacy Croteau and Dr. Craig Kessler.


2:00 - 3:30 PM
HEMOSTASIS / BASIC SCIENCE
HEPARIN-INDUCED THROMBOCYTOPENIA
Chair/Organizer: Gow Arepally , Mihir Bhatt

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



NEW APPROACHES TO THE LABORATORY DIAGNOSIS OF HIT
Anand Padmanabhan. Mayo Clinic


ROLE OF THE ENDOTHELIUM IN HIT PATHOGENESIS
Lubica Rauova. The Children's Hospital of Philadelphia/University of Pennsylvania


SPONTANEOUS HIT: PATHOGENESIS AND CLINICAL FEATURES
Ted Warkentin. McMaster University

2:00 - 3:30 PM
HEMOSTASIS
NOT YOUR EVERYDAY BLEEDING
Chair/Organizer: Stephanie Cloutier, Stacy Croteau

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



BLEEDING OF UNKNOWN CAUSE
Julie Jaffray. Children's Hospital of Los Angeles, University of Southern California Keck School of Medicine


BEYOND THE BLOOD VESSEL, CONNECTIVE TISSUE DISORDERS
Pamela Trapane. University of Florida College of Medicine - Jacksonville


GENDER DIFFERENCES IN BLEEDING & UNDERSTANDING THE BLEEDING TENDENCY IN HEMOPHILIA CARRIERS
Jill Johnsen. Bloodworks and University of Washington

2:00 - 3:30 PM
LABORATORY
UPDATES ON THE NEW GUIDELINES FOR THROMBOPHILIA TESTING
Chair/Organizer: Kristi Smock, Betsy Van Cott

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



GUIDELINES ON TESTING FOR ACTIVATED PROTEIN C RESISTANCE
Dot Adcock. Laboratory Corporation of America


GUIDELINES ON TESTING FOR PROTEIN C AND PROTEIN S
Richard Marlar. University of New Mexico


GUIDELINES ON TESTING FOR ANTITHROMBIN DEFICIENCY
Betsy Van Cott. Massachusetts General Hospital

4:15 - 6:15 PM
MEMBER EVENT
AC FORUM WORKSHOP: ANTICOAGULATION FORUM MINI BOOT CAMP
Chair/Organizer: Nathan Clark

Join world experts Dr. Scott Kaatz & Dr. Geoffrey Barnes in a rare opportunity to hear talks from the AC Forum Boot Camp curriculum. In addition, they will be joined by Dr. Nathan Clark for an engaging Q&A panel discussion during the "chalk talk". You can help to shape and drive cutting edge topics about caring for patients on anticoagulants and get your questions answered or cases discussed. Target Audience Description: This activity has been designed to meet the educational needs of physicians, pharmacists, registered nurses, and associated health professionals who work in the field of anticoagulation.



4:15

INTRODUCTION
Nathan Clark.


4:20

TOP ARTICLES FROM 2019 YOU NEED TO KNOW
Scott Kaatz.


5:00

BREAK.


5:15

COVID 19 & THROMBOSIS: A CASE-BASED DISCUSSION
Geoffrey Barnes.


5:45

LIVE CHALK TALK (FULL PANEL).


NASCOLA/ISLH WORKSHOP: INTERESTING CASES IN LABORATORY HEMOSTASIS AND THROMBOSIS
Chair/Organizer: Cathy Hayward, Kristi Smock

This joint ISLH/NASCOLA workshop will use a case-based format to highlight important and practical issues in coagulation testing such as strategies, methodologies, interpretation and reporting, and clinical application. The session will be interactive and participant questions and interactive discussion will be encouraged. Target Audience Description: physicians, nurses, laboratory professionals, pharmacists and others.



4:15

INTRODUCTION & WELCOME
Catherine Hayward, Kristi Smock.


4:20

ISLH CASE 1
Catherine Hayward.


4:35

ISLH CASE 2
Charles Eby.


4:50

ISLH CASE 3
Pall Onundarson.


5:05

NASCOLA CASE 1
Kristi Smock.


5:15

NASCOLA CASE 2
Andrew Goodwin.


5:25

NASCOLA CASE 3
Donna Castellone.


5:35

NASCOLA CASE 4
Nicole Zantek.


6:10

WRAP-UP AND CONCLUSION
Catherine Hayward, Kristi Smock.


5:45

Q&A WITH PRESENTERS.


NURSING WORKSHOP: IMPACT OF ADVANCES IN HEMOSTASIS AND THROMBOSIS ON THE ROLE OF THE NURSE IN THE COORDINATION OF CARE
Chair/Organizer: Chris Guelcher, Lynn Oertel


4:15

WELCOME
Chris Guelcher.


4:20

ADOLESCENT TRAUMA, IVC FILTERS AND ANTICOAGULATION
Christine Guelcher.


4:32

TRANSITION TO DOACS, SURGERY AND TRAUMA
Lynn Oertel.


4:44

CATASTROPHIC ANTIPHOSPHOLIPID ANTIBODY SYNDROME (CAPS): DOES IT EXIST?
Terri Schnurr.


4:56

MIS-C - THROMBOSIS RISK AND THE ROLE OF THE APP
Jennifer Meldau.


5:08

Q&A/PANEL DISCUSSION.


5:20

DIAGNOSTIC WORK-UP AND LABORATORY CHALLENGES
Kim Schafer.


5:32

ADULT ADHERENCE IN THE ERA OF EMICIZUMAB PROPHYLAXIS
Laurel McKernan.


5:44

TYPE 3 VWD WITH AN INHIBITOR - TREATMENT CHALLENGES
James Munn. Michigan Medicine


5:56

Q&A/PANEL DISCUSSION.


PLATELET DISORDER SUPPORT ASSOCIATION (PDSA) WORKSHOP: ITP JOURNAL CLUB

A panel of four leading international adult and pediatric specialists in Immune Thrombocytopenia (ITP) will hold an ITP journal club, moderated by James Bussel, MD. Each of the four experts will select and present a recent article of interest, either clinical or laboratory based, over approximately 10-15 minutes. A discussion of each article will follow, including questions from attendees.


7:00 - 8:00 PM
SHORT TALKS
BASIC SCIENCE OF HEMOSTASIS


EVALUATING THE ROLE OF SINGLE SITE GLYCAN MODIFICATION OF B-DOMAIN DELETED FACTOR VIII ON ANTI-FACTOR VIII EXPRESSION AND ANTIBODY BINDING
Jasmine C. Ito, John F. Healey, Hunter W. Baldwin, Ernest T. Parker, Shannon L. Meeks , Glaivy Batsuli. Aflac Cancer and Blood Disorders Center of Children, Atlanta, GA, USA


ANGIOGENIC ALTERATIONS IN VON WILLEBRAND DISEASE (VWD) AS A POSSIBLE CAUSE OF OCCULT BLEEDING IN THE STOMACH
Katharina Kaiser1, 2, Stefanie Lehner1, Hanna Allerkamp1, 2, Carsten Detering1, Mahnaz Ekhlasi-Hundrieser1, Christiane Pfarrer2, Mario von Depka1. 1Werlhof Institute, Hannover Germany. 2Institute of Anatomy, University of Veterinary Medicine, Hannover Germany


THE ROLE OF IGM REACTIVE TO THE C1 DOMAIN IN THE HUMORAL IMMUNE RESPONSE TO FACTOR VIII
Seema R Patel, Jasmine C Ito, Hunter W Baldwin, Courtney Cox, John Healey, Ernest Parker, Shannon L Meeks, Glaivy Batsuli. Aflac Cancer and Blood Disorders Center, Children, Atlanta, GA, USA


BLEEDING DISORDER THERAPY


WHAT TO DO WITH PATIENTS WITH TYPE 3 VWD AND VWF INHIBITORS? IS ITI ENOUGH?
Ahmad Al-Huniti, Vanessa Bouskill, Melanie Jackson, Caroline Malcolmson, Alyaa Al Mughairy, Manuel Carcao. The Hospital for Sick Children, Toronto, ON, Canada


AN INTERNATIONAL MULTICENTER STUDY OF BEVACIZUMAB FOR BLEEDING IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: THE INHIBIT-BLEED STUDY
Hanny Al-Samkari1, 2, Raj S. Kasthuri3, Joseph G. Parambil4, Hasan A. Albitar5, Carolina Vazquez6, Marcelo M. Serra6, Sophie Dupuis-Girod7, Craig B. Wilsen8, Justin P. McWilliams8, Evan H. Fountain9, James R. Gossage9, Clifford R. Weiss10, Assaf Issachar11, Mary E. Meek12, Miles Conrad13, Vivek N. Iyer5. 1Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA. 2Harvard Medical School, Boston, MA, USA. 3Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA. 5Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA. 6Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. 7Centre de Reference pour la maladie de Rendu-Osler, Hospices Civils de Lyon, Lyon, France. 8Division of Interventional Radiology, Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 9Division of Pulmonary, Critical Care, and Sleep Medicine, Augusta University, Augusta, GA, Augusta, GA, USA. 10Russel H. Morgan Department of Radiology and Radiological Science, Division of Interventional Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 11Schneider Children, Tel Aviv, Israel. 12Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 13Department of Radiology, University of California San Francisco Medical Center, San Francisco, CA, USA


EFFICACY AND SAFETY OF SIMOCTOCOG ALFA IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HAEMOPHILIA A: FINAL RESULTS FROM THE NUPROTECT STUDY
Ri J Liesner1, Ellis J Neufeld2, on behalf of the NuProtect Study Group1. 1Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom. 2St. Jude Children, Memphis, TN, USA


TREATMENT OF IMMUNE THROMBOCYTOPENIA WITH THE SPLEEN TYROSINE KINASE INHIBITOR FOSTAMATINIB: RESTORING HEMOSTATIC BALANCE WHILEAVOIDING A PROTHROMBOTIC STATE
Ivy Altomare1, Vadim Markovtsov2, Leslie Todd2, Dheepika Weerasinghe2, Robert P Numerof2, Sandra Tong2, Esteban Masuda2, James B Bussel3. 1Duke University School of Medicine, Durham, NC, USA. 2Rigel Pharmaceuticals, Inc, South SanFrancisco, CA, USA. 3New York Presbyterian Hosp. Weill Cornell Medical Center, New York, NY, USA


USE OF EMICIZUMAB PROPHYLAXIS IN ADULT AND PEDIATRIC HEMOPHILIA A PATIENTS WITH AND WITHOUT INHIBITORS. SINGLE CENTER EXPERIENCE.
Natalie A. Montanez, Donna Oldfield, Stephanie Gustafson, Joanna Larson, Nidra I. Rodriguez, Neethu Menon, Deborah Brown, Miguel A. Escobar. University of Texas Health Science Center and Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA


LABORATORY 1


COAGULATION AND CIRCULATING HEPARIN PROFILE IN PATIENTS WITH END-STAGE RENAL DISEASE UNDERGOING MAINTENANCE HEMODIALYSIS
Emily Bontekoe, Arjun Grewal, Jasdeep Bajwa, Nausheen Baig, Melissa Mazariegos, Vinod Bansal, Fakiha Siddiqui, Omer Iqbal, Debra Hoppensteadt, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


ASSESSMENT OF A NEW CHROMOGENIC FVIII ASSAY IN SEVERE HAEMOPHILIA A PLASMA CONTAINING EMICIZUMAB
Annette Bowyer, Steve Kitchen, Richard Wardle, Rhona Maclean. Sheffield Haemophilia and Thrombosis Centre, Sheffield, United Kingdom


THE UTILIZATION OF DOAC-STOP IN LABORATORY INVESTIGATION OF LUPUS ANTICOAGULANT FOR PATIENTS ON DIRECT ORAL ANTICOAGULANTS
Jing Jin1, Chris Pfaffroth1, Trang Vu1, Steven Baker2, James Zehnder2, 3. 1Department of Special Coagulation Clinical laboratory, Stanford Health Care, Palo Alto, CA, USA. 2Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA. 3Division of Hematology, School of Medicine, Stanford University, Stanford, CA, USA


THE INFLUENCE OF EMICIZUMAB (EMI) ON GLOBAL HEMOSTASIS IS BETTER MEASURED BY THROMBIN GENERATION ASSAY (TGA) THAN THROMBOELASTOGRAPHY
Erika J Martin1, Gita V Massey2, Janice G Kuhn1. 1Virginia Commonwealth University, Richmond, VA, USA. 2Children, Richmond, VA, USA


CHILDREN AND YOUNG ADULTS MANIFEST SEVERE COVID-19 COAGULOPATHY
William B Mitchell1, Jennifer Davila1, Janine Keenan1, Jenai Jackson1, Adit Tal1, Kerry A Morrone1, Ellen J Silver1, Sarah O'Brien2, Deepa Mawani1. 1Albert Einstein College of Medicine, Bronx, NY, USA. 2Nationwide Children, Cincinnati, OH, USA


THROMBOSIS: DIAGNOSIS AND MANAGEMENT


OPTIMIZING THROMBOPROPHYLAXIS USE IN PEDIATRIC ORTHOPEDIC SURGERY THROUGH IMPLEMENTATION OF A VENOUS THROMBOEMBOLISM RISK SCREENING TOOL
Wyatt MacNevin1, Kedar Padhye2, Yasser Alkhalife2, Victoria Price1, Ron El-Hawary2, Brian R. Branchford3, Sarah Stevens4, Ketan Kulkarni1. 1Division of Pediatric Hematology Oncology, Department of Pediatrics, IWK Health Centre, Halifax, NS, Canada. 2Division of Orthopaedics, IWK Health Centre, Halifax, NS, Canada. 3Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA. 4Department of Anesthesiology, IWK Health Centre, Halifax, NS, Canada


ANALYSIS OF MANAGEMENT STRATEGIES FOLLOWING SLIGHTLY OUT OF RANGE INRS: WATCHFUL WAITING VS. ANY DOSE CHANGES
Hallie B. Remer1, Xiaokui Gu1, Brian Haymart1, Geoffrey D. Barnes1, Mona Ali2, Eva Kline-Rogers1, Tina Alexandris-Souphis1, Jay Kozlowski3, James B. Froehlich1, Vinay Shah4, Greg Krol4, Scott Kaatz4. 1University of Michigan, Ann Arbor, MI, USA. 2Beaumont Hospital, Royal Oak, MI, USA. 3Detroit Medical Center, Detroit, MI, USA. 4Henry Ford Health System, Detroit, MI, USA


OVERUTILIZATION OF VENOUS DOPPLER ULTRASONOGRAPHY TO DETECT DEEP VEIN THROMBOSIS IN INTENSIVE CARE UNITS
Sophie Samuel1, Thuy Nguyen1, James Beeson1, Thanh Dao1, Liang Zhu2, Louise D McCullough2. 1Memorial Hermann Medical Center, Houston, TX, USA. 2Univeristiy of Texas. McGovern Medical School, Houston, TX, USA


RESULTS OF THE PEGASUS PHASE 3 RANDOMIZED TRIAL DEMONSTRATING SUPERIORITY OF THE C3 INHIBITOR, PEGCETACOPLAN, COMPARED TO ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Ilene Weitz1, Hillmen Peter2, Szer Jeff3, Alexander Roth4, Britta Hochsmann5, Jens Panse6, Kensuke Usuki7, Morag Griffin2, Jean-Jacques Kiladjian8, Carlos de Castro9, Hisakazu Nishimori10, Mohamed Hamdani11, Temitayo Ajayi11, Antonio Risitano12, Regis Peffault de Latour13, on behalf of PEGASUS investigators . 1Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine, Los Angeles, CA, USA. 2Department of Haematology, St James's University Hospital, Leeds United Kingdom. 3Department of Clinical Haematology, Peter MacCallum Cancer Center a Royal Melbourne Hospital, Melbourne Australia. 4Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen Germany. 5Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm Germany. 6Department of Oncology, Hematologiy, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen Germany. 7NTT Medical Center Tokyo, Tokyo Japan. 8Centre d'Investigations Cliniques, Hopital Saint-Louis Assistance Publique, Paris France. 9Duke University School of Medicine, Durham, NC, USA. 10Department of Hematology and Oncology, Okayama University Hospital, Okayama Japan. 11Apellis Pharmaceuticals, Waltham, MA, USA. 12Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino Italy. 13French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Assistance Publique, Paris France


PREVALENCE, TRENDS, PREDICTORS AND OUTCOMES OF PORTAL VEIN THROMBOSIS IN HOSPITALIZED PANCREATIC CANCER PATIENTS: A NATIONWIDE INPATIENT SAMPLE DATABASE ANALYSIS FROM 1998-2016
Yu Zhao1, Hussam Alhasson1, Peng Cai2, Anas Saad3, Muneer Al-Husseini4. 1Department of Internal Medicine, Rochester Regional Health- Unity Hospital, Rochester, NY, USA. 2Department of Mathematical Sciences, Worcester Polytechnic Institute, Worcester, MA, USA. 3Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH, USA. 4Department of Internal Medicine, Ascension St John Hospital, Detroit, MI, USA

7:00 - 7:45 PM
POSTER SESSION
VIRTUAL POSTERS - ANTICOAGULATION CLINICS

Welcome to this Virtual Poster Session. You may view any poster by clicking on a presentation below. Note that you may also submit questions directly to the author of any presentation using the Ask a Question option. Note that all questions may not receive a response.



A1. ANTICOAGULATION CLINICS


1

EVALUATION OF THE VALIDITY OF SAME-TT2R2 SCORE IN A COHORT OF VENOUS THROMBOEMBOLISM PATIENTS TREATED WITH WARFARIN IN QATAR
Eman Alhmoud1, Mohammed Abdulgelil2, Walid Mekkawi2, Osama Abd El Samad1, Hazem Elewa3, Abdelnasser Elzouki 2. 1Al-Wakra Hospital, Doha, Qatar. 2Hamad General Hospital, Doha, Qatar. 3Qatar University-College of Pharmacy, Doha, Qatar


2

THE RELATIONSHIP BETWEEN MISSED APPOINTMENTS AND ANTICOAGULATION OUTCOMES IN AN INNER CITY, SOCIOECONOMICALLY DISADVANTAGED POPULATION: A PROSPECTIVE COHORT STUDY
Ali Alobaidi1, Crissel Marie Arban1, Connie H. Yan1, Sandra Walko1, Miranda Kopfman1, Maryam Naveed1, Lisa K. Sharp1, 2, Edith Nutescu1, 2. 1Department of Pharmacy Systems, Outcomes, and Policy, University of Illinois at Chicago, Chicago, IL, USA. 2Center for Pharmacoepidemiology a Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, USA


3

REMOTE WARFARIN MANGEMENT USING EKITE; AN INNOVATIVE LEARNING EXPEREINCE WITH HOME INR MONITORING
MARY BAUMAN1, 2, CHRISTINA VANDERPLUYM3, RUKHMI BHAT4, EWURABENA SIMPSON6, MARY MEHEGAN5, PATRICIA MASSICOTTE1, 2. 1Stollery childrens hospital, Edmonton, AB, Canada. 2university of Alberta, Edmonton, AB, Canada. 3boston childrens hospital, Boston, MA, USA. 4lurie childrens hospital, Chicago, IL, USA. 5St louis childrens hospital, St Louis, WA, USA. 6childrens hospital of eastern ontario, Ottawa, ON, Canada


4

COMPARING THE EFFECTIVENESS AND SAFETY OF RESTARTING WARFARIN USING LOADING DOSES VERSUS MAINTENANCE DOSES FOLLOWING AN ELECTIVE DAY PROCEDURE: A RETROSPECTIVE STUDY
Joey J. Champigny, Jeff Nagge, Caitlin Carter. University of Waterloo, Kitchener, ON, Canada


5

CREATION OF A NEONATAL THROMBOSIS CENTER AND ITS USE TO SUCCESSFULLY TREAT INFANTS WITH SEVERE THROMBOSES
Elizabeth Gunn3, Shailly Gaur3, Matthew Saxonhouse2, 3, Ashley Hinson1, 3. 1Division of Cancer and Blood Disorders, Charlotte, NC, USA. 2Division of Neonatology, Charlotte, NC, USA. 3Department of Pediatrics, Levine Children's Hospital, Charlotte, NC, USA


6

IMPLEMENTATION OF A PROCESS IMPROVEMENT INITIATIVE OPTIMIZES THE MANAGEMENT OF VENOUS THROMBOEMBOLISM IN THE OUTPATIENT SETTING OF A COMMUNITY HEALTH CENTRE.
Christie Kim, Connie Vo. St. Joseph Health Centre, Toronto, ON, Canada


7

EFFECT OF POLYPHARMACY ON TIME IN THERAPEUTIC RANGE OF WARFARIN THERAPY IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
Shaban Mohammed1, 4, Mohamed Kasem1, Amer Aljundi1, Mohammed Alhashemi2, Ayman El-Menyar3, 5, Osama Abd El Samad1, Moza Al Hail1, Nidal Asaad2. 1Pharmacy Department, Hamad Medical Corporation, Doha, Qatar. 2Heart Hospital, Hamad Medical Corporation, Doha, Qatar. 32Department of Clinical Medicine, Weill Cornel Medical College, Doha, Qatar. 4American University of Barbados School of Medicine, Barbados, Barbados, Barbados. 53Department of Surgery, Clinical Research, Hamad Medical Corporation, Doha, Qatar


8

EVALUATION OF A POPULATION-BASED MANAGEMENT TOOL IN IDENTIFYING POTENTIAL INTERACTIONS BETWEEN DIRECT ORAL ANTICOAGULANTS AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AT A VETERANS AFFAIRS HEALTH CARE SYSTEM
Liem T. Nguyen, Rebecca F. Edwards, Jon E. Folstad, Juan D. Mobley, Jina W. Almond. Salisbury VA Health Care System, Salisbury, NC, USA


9

DRVV TESTING ON PATIENTS RECIEVING ANTICOAGULANT THERAPY
Maria Notini1, Dr. Thomas L Ortel2. 1Duke Health System, durham, NC, USA. 2Duke Health System, durham, NC, USA


10

A RETROSPECTIVE EVALUATION OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN OBESE END STAGE RENAL DISEASE (ESRD) PATIENTS
Tanvi Patil1, Abraham B Gebremariam2, Alamdeep Kaur1. 1Veterans health Administration, Salem, VA, USA. 2Applachian University school of Pharmacy, Oakwood, VA, USA


11

OPERATIONAL MODEL OF A PERIOPERATIVE ANTICOAGULATION AND BRIDGING CLINIC: A CASE STUDY
Laurie A. Sardo1, 2, Noah H. Spencer1, James Douketis1, 3, Joanne P. Cordell4, Julia Bayadinova1. 1St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada. 2Department of Nursing, McMaster University, Hamilton, ON, Canada. 3Department of Medicine, McMaster University, Hamilton, ON, Canada. 4Cordell Limited, Toronto, ON, Canada


12

COMPARABILITY OF POINT OF CARE VERSUS LABORATORY INR METHODS WITH VENOUS AND CAPILLARY SPECIMENS
Roona Sinha1, Nancy Hodgson2, Sibasis Daspal1, Matthew Bradshaw1, Lyon Martha1. 1University of Saskatchewan, Saskatoon, SK, Canada. 2Saskatchewan Health Authority, Saskatoon, SK, Canada


13

POINT-OF-CARE COAGULATION MONITORING USING A NOVEL OPTICAL SENSOR IN PATIENTS UNDERGOING CARDIAC SURGERY
Diane Malu Tshikudi1, 2, Alexandra G. Wirth1, 2, Michael N. Andrawes2, Seemantini K. Nadkarni1, 2, 3. 1Wellman Center for Photomedicine, Boston, MA, USA. 2Massachusetts General Hospital, Boston, MA, USA. 3Harvard Medical School, Boston, MA, USA


VIRTUAL POSTERS - ANTITHROMBOTIC THERAPY

Welcome to this Virtual Poster Session. You may view any poster by clicking on a presentation below. Note that you may also submit questions directly to the author of any presentation using the Ask a Question option. Note that all questions may not receive a response.



A8. ANTITHROMBOTIC THERAPY


1

IS THERE A NEED FOR ANTICOAGULATION FOR NEW-ONSET ATRIAL FIBRILLATION IN SEPSIS: A NARRATIVE REVIEW
Jesus Aibar1, 2, Sam Schulman2. 1Internal Medicine Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain. 2Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada


2

EFFECTIVENESS AND SAFETY OF PRIMARY THROMBOPROPHYLAXIS IN PEDIATRIC RENAL TRANSPLANT: A SYSTEMATIC REVIEW OF THE LITERATURE AND META-ANALYSIS
Ahmad Al-Huniti, Caroline Malcolmson, Armando Lorenzo, Valerie Langlois, Suzan Williams, Chia Wei Teoh, Leonardo Brandao. The hospital for sick children, Toronto, ON, Canada


3

STANDARDIZATION OF DIRECT ORAL ANTICOAGULANT MANAGEMENT ACROSS A HEALTH SYSTEM
J Burdick, C Patterson, A Rose. University of Wisconsin Hospital and Clinics, Madison, WI, USA


4

SHORT-TERM OUTCOMES OF CATHETER-RELATED ARTERIAL THROMBOSIS IN NEONATES AND CHILDREN
Clay T Cohen1, 2, Viia Anderson1, 2, Kristen A Staggers1, Rosa Diaz1, 2. 1Baylor College of Medicine, Houston, TX, USA. 2Texas Children's Hematology and Cancer Centers, Houston, TX, USA


5

SULODEXIDE AS A PARENTERAL ANTICOAGULANT. A SUBSTITUTE FOR UNFRACTIONATED HEPARIN.
Bharathi Daravath1, Emily Bontekoe1, Ahmed Kouta1, Omer Iqbal1, Christopher Lattimer2, Jawed Fareed1. 1Loyola University Medical Center, Maywood, IL, USA. 2Ealing Hospital, London United Kingdom


6

WHOLE BLOOD ANTICOAGULANT EFFECTS OF SULODEXIDE AS MEASURED BY ACTIVATED CLOTTING TIME AND THEIR NEUTRALIZATION BY PROTAMINE SULFATE
Bharathi Daravath, Omer Iqbal, Debra Hoppensteadt, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


7

MANAGEMENT OF PULMONARY EMBOLISM AND CEREBRAL VENOUS SINUS THROMBOSIS IN CHILDREN WITH LEUKEMIA
Melanie Degliuomini1, 2, Victoria Cooley3, Elizabeth Mauer3, Linda Gerber3, Suchitra Acharya4, Nicole Kucine1. 1Weill Cornell Medicine, Department of Pediatrics, New York, NY, USA. 2Memorial Sloan Kettering Cancer Center, Department of Pediatrics, New York, NY, USA. 3Weill Cornell Medicine, Department of Healthcare Policy and Research, New York, NY, USA. 4Cohen Children's Medical Center, Northwell Health, New Hyde Park, NY, USA


8

GENOME-WIDE ANALYSIS OF WARFARIN PHARMACOGENOMICS IN PATIENTS FROM THE MIDDLE EAST AND NORTH AFRICAN REGION
Nihal El Rouby1, Mohamed Shahin2, Loulia Bader3, Hazem Elewa3. 1University of Cincinnati, Cincinnati, OH, USA. 2Pfizer Global Research, Groton, CT, USA. 3College of Pharmacy, Qatar University, Doha, Qatar


9

VENOUS THROMBOEMBOLISM INCIDENCE AMONG PATIENTS RECOMMENDED FOR PHARMACOLOGIC THROMBOEMBOLISM PROPHYLAXIS AFTER CESAREAN DELIVERY IN SELECTED GUIDELINES
Jerome J Federspiel1, 2, Lauren E Wein1, Kateena L Addae-Konadu1, Kristin C Darwin2, Laura E Talamo3, Evan R Myers4, 5, Andra H James1. 1Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC, USA. 2Department of Gynecology and Obstetrics, The Johns Hopkins School of Medicine, Baltimore, MD, USA. 3Division of Hematology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. 4Division of Reproductive Sciences, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC, USA. 5Duke Clinical Research Institute, Durham, NC, USA


10

EVALUATION OF ANTICOAGULATION REGIMENS IN PATIENTS WITH COVID-19
Leila Forouzan, Alyssa Pagliaro, Veronika Colomy, Robert Wright, Travis Reinaker, John Knorr. Einstein Medical Center Philadelphia, Philadelphia, PA, USA


11

EVALUATION OF ANTICOAGULATION PHARMACOTHERAPY AND CLINICAL OUTCOMES FOR ACUTE COMMUNITY-ACQUIRED VENOUS THROMBOEMBOLISM DIAGNOSED IN THE EMERGENCY DEPARTMENT
Thao N. Huynh1, Matthew E. Borrego1, Allison E. Burnett1, 2, Lisa R. Koselke2, Dusadee Sarangarm2, 3, Gregory C. Hadlock4. 1University of New Mexico College of Pharmacy, Albuquerque, NM, USA. 2University of New Mexico Hospital, Albuquerque, NM, USA. 3University of New Mexico Department of Emergency Medicine, Albuquerque, NM, USA. 4Presbyterian Healthcare Services, Albuquerque, NM, USA


12

COMPARISON OF PERCENT ADJUSTED AND PREDEFINED INCREMENTAL ADJUSTED ARGATROBAN DOSING NOMOGRAMS: MORE FREQUENT MONITORING DOES NOT IMPROVE TIME TO THERAPEUTIC ANTICOAGULATION
Mark E. Jao, Eric R. Wenzler, Keri S. Kim. University of Illinois at Chicago, Chicago, IL, USA


13

THE OVERUSE OF UNFRACTIONATED HEPARIN (UFH) VERSUS LOW MOLECULAR WEIGHT HEPARIN (LMWH) IN HOSPITALIZED PATIENT WITH ACUTE DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE)
Steven J. Jubelirer1, Saranya Dinesan1, Christine A. Welch2, Talia E. Alexander1, Mitchell L. Stanley1. 1Charleston Area Medical Center/West Virginia University, Charleston, WV, USA. 2Charleston Area Medical Center/ Outcomes Research, Charleston, WV, USA


14

CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF PATIENTS RECEIVING ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE FOR APIXABAN AND RIVAROXABAN ASSOCIATED MAJOR BLEEDING
John M. Koerber1, 3, Karissa Fritsch1, Janet L. Hoffman1, 3, Sean Mertz2, Nour Baalbaki1, Fatme Chehab3, Maureen A. Smythe1, 3. 1Beaumont Heatlh, Royal Oak, MI, USA. 2Cleveland Clinic, Cleveland, OH, USA. 3Wayne State University, Detroit, MI, USA


15

TITLE: FIXED-DOSE 1500 UNIT 4F-PCC FOR APIXABAN OR RIVAROXABAN REVERSAL IN MAJOR BLEEDING
Jamie Kooiman, Sean Lujan, Lisa Anselmo, Mindy Mason, Chelsea Rodriguez, Allison Burnett. University of New Mexico Hospital, Albuquerque, NM, USA


16

USP POTENCY EQUATED BOVINE MUCOSAL HEPARINS ARE COMPARABLE TO PORCINE MUCOSAL HEPARIN AND MAY BE INTERCHANGEABLE FOR ANTICOAGULATION.
Ahmed Kouta, Walter Jeske, Debra Hoppensteadt, Massimo Iacobelli, Omer Iqbal, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


17

SHEEP MUCOSAL HEPARIN AS A SUBSTITUTE FOR PORCINE MUCOSAL HEPARIN. A VIABLE OPTION TO ADDRESS THE POTENTIAL SHORTAGE CRISIS.
Ahmed Kouta1, Jawed Fareed1, Walter Jeske1, Debra Hoppensteadt1, Omer Iqbal1, Emily Bontekoe1, Massimo Iacobelli1, Yiming Yao2. 1Loyola University Medical Center, Maywood, IL, USA. 2Ronnsi Pharma, LTD, Suzhou China


18

SEROPREVALENCE OF PRE-EXISTING NABS AGAINST AAV1, 2, 5, 6 AND 8 IN A SOUTH AFRICAN HEMOPHILIA PATIENT POPULATION
Anna Majowicz1, Nolukholo Ncete2, Floris van Waes1, Nikki Timmer1, Sander J van Deventer1, Johnny N Mahlangu2, Valerie Ferreira1. 1uniQure B. V, Amsterdam, Netherlands. 2Hemophilia Comprehensive Care Center, Johannesburg, South Africa


19

PREVALENCE AND AFFINITY/AVIDITY ASSESSMENT OF PRE-EXISTING NABS AGAINST AAV1, 2, 5, AND 8, ANALYZED IN THE SERUM OF 300 HEALTHY DONORS
Anna Majowicz, Floris van Waes, Nikki Timmer, Sander J van Deventer, Valerie Ferreira. uniQure B. V, Amsterdam, Netherlands


20

THROMBOSIS AND ORAL ANTICOAGULATION IN PEDIATRICS PATIENTS: NOW IT IS POSSIBLE TO IMPROVE THE QUALITY OF LIFE AND CLINICAL SAFETY WITH THE “COAGULIN PROJECT”
RAFAEL MARTOS1, MARIA YUSTE1, ELENA GONZALEZ1, LAURA BERMEJO2, PILAR BELTRAN2, ADRIANA PASCUAL2, DELIA CORNEJO1, PILAR LLAMAS1, 2, 3. 1HOSPITAL GENERAL UNIVERSITARIO DE VILLALBA, MADRID, Spain. 2HOSPITAL UNIVERSITARIO INFANTA ELENA DE VALDEMORO, MADRID, Spain. 3HOSPITAL UNIVERSITARIO FUNDACION JIMENEZ DIAZ, MADRID, Spain


21

RETROSPECTIVE QUALITY ASSURANCE STUDY FOR POTENTIAL P2Y12 RECEPTOR INHIBITOR INTERFERENCE OF SEROTONIN RELEASE ASSAY (SRA) DETECTING ANTIBODIES ASSOCIATED WITH HEPARIN INDUCED THROMBOCYTOPENIA (HIT) IN PATIENT SPECIMENS
Morgan H. McCoy1, Charles S. Davis2, Komal A. Pandya1, George A. Davis1. 1University of Kentucky Medical Center, Lexington, KY, USA. 2University of Kentucky College of Pharmacy, Lexington, KY, USA


22

RETROSPECTIVE ANALYSIS OF FOUR FACTOR PROTHROMBIN COMPLEX CONCENTRATE USE IN EMERGENCY DEPARTMENT PATIENTS OVER THREE YEARS: A SINGLE CENTER EXPERIENCE
Hannah L McRae1, Ferhat Kara1, Nicole Acquisto2, Majed Refaai1. 1Department of Pathology and Laboratory Medicine, Transfusion Medicine Unit, University of Rochester Medical Center, Rochester, NY, USA. 2Departments of Pharmacy and Emergency Medicine, University of Rochester Medical Center, Rochester, NY, USA


23

DESCRIBING THE USE OF COAGULATION FACTOR XA (RECOMBINANT), INACTIVATED-ZHZO (ANDEXANET ALFA) AT A MULTICENTER HEALTH SYSTEM
Krishna Modi, Dana Attar, Philip Kuriakose , Jona Lekura, Gerald Koenig, Long To, Michael Hudson, Panayiotis Mitsias , Abdul-Nasser Charara, James Kalus, Norm Buss, Mohammed Rehman, Scott Kaatz. Henry Ford Health System, Detroit, MI, USA


24

VARIABILITY IN LOW MOLECULAR WEIGHT HEPARIN ANTI-XA ASSAYS BETWEEN MANUFACTURERS
Karen A Moffat1, 2, Siraj Mithoowani1, Akash Gupta1, Stephen A Carlino2, Mark A Crowther1. 1Department of Medicine, McMaster University, Hamilton, ON, Canada. 2Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada


25

SUCCESSFUL TREATMENT OF PEDIATRIC CEREBRAL VENOUSTHROMBOSIS STROKEWITH BIVALIRUDIN
Oluwaseun Olaiya, Sana Farooki, Mukta Sharma. Children's Mercy Hospital, Kansas City, MO, USA


26

BUNDLE APPROACH IN VENOUS THROMBOEMBOLISM PROPHYLAXIS IN PATIENTS WITH NON-TRAUMATIC SUBARACHNOID HEMORRHAGE
Brian V. Phan1, Lolita Fagaragan2, Ali Alaraj2, Keri S. Kim2. 1Riverside University Health System, Moreno Valley, CA, USA. 2University of Illinois Health, Chicago, IL, USA


27

RECENT PROGRESS IN THE DEVELOPMENT PROGRAM OF AMT-061 (ETRANACOGENE DEZAPARVOVEC) FOR PERSONS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA B
Steven W Pipe1, Wolfgang Miesbach2, Annette Von Drygalski3, Adam Giermasz4, Karina Meijer5, Michiel Coppens6, Peter Kampmann7, Robert Klamroth8, Roger Schutgens9, Nigel S Key10, Susan Lattimore11, Michael Recht11, Esteban Gomez13, Giancarlo Castaman14, Eileen K Sawyer12, Robert Gut12. 1University of Michigan, Ann Arbor, MI, USA. 2University Hospital Frankfurt, Frankfurt, Germany. 3University of California San Diego, San Diego, CA, USA. 4University of California Davis, Sacramento, CA, USA. 5University Medical Center Groningen, Groningen, Netherlands. 6Academic Medical Center, Amsterdam, Netherlands. 7Rigshospitalet, Copenhagen, Denmark. 8Vivantes Klinikum, Berlin, Germany. 9University Medical Center, Utrecht, Netherlands. 10University of North Carolina, Chapel Hill, NC, USA. 11Oregon Health a Science University, Portland, OR, USA. 12uniQure biopharma B. V, Lexington, MA, USA. 13Phoenix Children's Hospital, Phoenix, AZ, USA. 14Azienda Ospedaliera Universitaria Careggi, Florence, Italy. 15Erasmus University Medical Center, Rotterdam, Netherlands


28

UTILIZATION OF APIXABAN AND RIVAROXABAN LEVELS IN CLINICAL PRACTICE
Anne E Rose1, Erin N Robinson1, Cameron J Patterson1, Katherine A Cinnamon1, David J Ciske2. 1UW Health, Madison, WI, USA. 2University of Wisconsin Medical Foundation, Madison, WI, USA


29

THERAPEUTIC DILEMMA: MANAGING PHLEGMASIA CERULEA DOLENS IN A PEDIATRIC PATIENT WITH SEVERE CHRONIC REFRACTORY IMMUNE THROMBOCYTOPENIA
Penelope Sandiford1, Melissa Rose1, Patrick Warren2, Riten Kumar1. 1Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Department of Pediatrics, The Ohio State University, Columbus, OH, USA. 2Division of Interventional Radiology, Nationwide Children's Hospital, Department of Radiology, The Ohio State University, Columbus, OH, USA


30

DIFFERENCES IN THE CLOT BASED AND AMIDOLYTIC ANTI-XA ASSAYS BETWEEN THE NEUTRALIZATION PROFILE OF APIXABAN, BETRIXABAN, EDOXABAN AND RIVAROXABAN
Fakiha Siddiqui1, Alfonso Tafur2, Debra Hoppensteadt1, Emily Bontekoe1, Walter Jeske1, Bruce Lewis1, Omer Iqbal1, Jawed Fareed1. 1Loyola University Medical Center, Maywood, IL, USA. 2Northshore Health Systems, Skokie, IL, USA


31

ENHANCEMENT OF THROMBIN GENERATION IN LYMPHOMA COHORT BY ANDEXANET ALFA
Fakiha Siddiqui1, Emily Bontekoe1, Darko Antic2, Debra Hoppensteadt1, Grigoris Gerotziafas3, Ismail Elalamy3, Jawed Fareed1. 1Loyola University Medical Center, Maywood, IL, USA. 2Clinical Center for Hematology, Belgrade Serbia. 3Tenon University Hospital, Paris France


32

DEVELOPMENT AND IMPLEMENTATION OF A SYSTEM BASED INTERVENTION FOR HEALTHCARE-ASSOCIATED VENOUS THROMBOEMBOLISM PROPHYLAXIS AT A SAFETY NET ACADEMIC MEDICAL CENTER
Alyssa E. Utz1, Michael Knauss1, Palak K. Patel1, Mikhail Y. Akbashev2. 1Grady Health System, Atlanta, GA, USA. 2Emory University School of Medicine, Atlanta, GA, USA


33

INTERIM RESULTS FROM A FEASIBILITY STUDY OF THE FEARON ALGORITHM IN WARFARIN PATIENT SELF-MANAGEMENT
Daniel Witt1, Sara Vazquez1, Aubrey Jones1, John Saunders1, Paul Wegner2, Michael Fearon3. 1University of Utah, Salt Lake City, UT, USA. 2Epitome Pharmaceuticals, San Diego, CA, USA. 3Epitome Pharmaceuticals, Halifax, NS, Canada


34

CLINICAL OUTCOMES FOLLOWING ADMINISTRATION OF 4F-PCC FOR MANAGEMENT OF BLEEDING OR NEED FOR EMERGENT PROCEDURE ON A XA INHIBITOR- GOOD ENOUGH, OR DO WE NEED OTHER AGENTS?
Maura K. Wychowski, Christina I. Ruscio, Ronald L. Sham, Peter A. Kouides. Rochester General Hospital, Rochester, NY, USA